Mereo BioPharma (MREO) FCF Margin (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly FCF Margin of 1530.2% for Q2 2025, down 125.39% on a QoQ basis from 678.9% in Q4 2023.
Mereo BioPharma (MREO) FCF Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported FCF Margin for 2 consecutive years, with 1530.2% the latest figure, recorded in Q2 2025.
- Quarterly FCF Margin changed N/A year-over-year to 1530.2% in Q2 2025, while the trailing twelve-month figure through Dec 2025 was 6198.2% (changed N/A YoY) and the FY2025 annual result came in at 6198.2%, changed N/A from the prior year.
- FCF Margin slipped to 1530.2% in Q2 2025 per MREO's latest filing, from 678.9% in the prior quarter.
- Over the last five years, FCF Margin for MREO reached as high as 678.9% in Q4 2023 and fell as low as 1530.2% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mereo BioPharma | 232.52 Mn | 232.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1,530.20% |
| Dec 31, 2023 | -678.90% |